According to the incomplete statistics of the People's Daily health client, there were 23 investment and financing incidents in the national medical and health field this week (February 14-18), of which 7 cases of financing exceeded 100 million yuan, and many pharmaceutical companies such as Qinhao Pharmaceutical, Tiankeya, Jingyu Medical and other pharmaceutical companies obtained more than 100 million yuan of financing, involving anti-tumor new drugs, human vaccine research and development, tumor minimally invasive and other related fields, and the investors included Sequoia China, Hillhouse Capital, Huaxing Capital and other investment institutions.
Biomedicine
Qinhao Pharmaceutical: Completed hundreds of millions of yuan of B round financing, focusing on the research and development of original anti-tumor small molecule new drugs
On February 14, Qinhao Pharmaceutical (Suzhou) Co., Ltd. announced the completion of a series B financing of hundreds of millions of yuan. This round of financing is led by Lingcheng Venture Capital, qiandao fund, Panyi investment, Guohai Innovation Capital and other institutions jointly followed, and the old shareholder Lenovo Star continued to invest additionally.
It is reported that Qinhao Pharmaceutical is an innovative biomedical company facing the world, focusing on the research and development of original anti-tumor small molecule new drugs, headquartered in Suzhou Industrial Park. In 2021, Qinhao Pharmaceutical's GH35 product (KRAS G12C inhibitor) completed the first case of drug delivery; GH21 product (SHP2 inhibitor) received clinical approval from China and the United States, and the US clinical department was responsible for The First Patient Administration in January 2022, which was responsible for The First Patient Administration by Qinhao's strategic partner Huya Bio International. Tiankeya: Completed a new round of financing of more than 300 million yuan, leading the development of innovative immune cell drugs
On February 16, Tiankeya, a leading company in the field of immune cell therapy, announced the completion of a new round of financing of more than 300 million yuan.
This round of financing is led by AstraZeneca CICC Medical Industry Fund and Jianxin (Beijing) Investment Fund, and jointly invested by old shareholders ETP, Sharing Investment, DT Capital and Fang Group.
Founded in 2016, Tiankeya Company is an immune diagnostic and precision medicine solution provider, focusing on the innovative research and development of tumor immunotherapy technology and the clinical verification of combined treatment strategies, focusing on the innovative research and development of tumor immunotherapy technology and the clinical verification of combined treatment strategies, mainly providing personalized precision immune cell therapy solutions and gene modification products for a series of tumors such as lung cancer, liver cancer, cervical cancer, head and neck cancer, rhinitis cancer and so on.
Higshengko: Completed tens of millions of yuan of angel ++ round of financing, accelerating the targeted drug research and development pipeline to clinical trials
On February 16, Sigshengko (Shenzhen) Co., Ltd., a cancer innovation targeted drug research and development company based on disease model + AI, announced that it has completed the angel ++ round of financing support from Songhe Capital of tens of millions of yuan. This round of funding is the third round of funding completed by the company in one year.
Higsbio is an innovative targeted drug development company for cancer based on disease models. This round of funds will be used to accelerate the rapid advancement of the three innovative targeted drug R&D pipelines under development to clinical trials, and to promote the expansion and application of the existing disease model platform, as well as to strengthen the construction of their own R&D teams and promote the improvement of independent innovation capabilities.
Medical devices
Ganavi Medical: Completed hundreds of millions of yuan of financing, laying out a variety of fields of minimally invasive oncology and smart medical treatment
On February 15, Ganavi Medical, a high-quality medical device company dedicated to precision treatment solutions in the field of minimally invasive, announced the completion of hundreds of millions of yuan of B round financing.
This round of financing is led by Hangshi Asset Management, and Haier Capital follows. The financing will be used for the company's investment in the sustainable development of precision minimally invasive and smart medical fields, and further build the dominant position of Ganawi Medical in the relevant track.
The business of Zhejiang Ganavi Medical Technology Co., Ltd. covers four major areas: minimally invasive oncology, peripheral intervention, fine surgery and intelligent medical treatment. In the field of precision medicine, we adhere to "minimally invasive" and "intelligent", and have now formed a perfect series of minimally invasive ablation products that meet the needs of different clinical conditions. Among them, the percutaneous biopsy needle series and tumor radiofrequency ablation needle series products have all been put on the market.
Langmai Medical: Completed a new round of financing of 100 million yuan, focusing on orthopedic minimally invasive
On February 15, Shanghai Langmai Medical Device Technology Co., Ltd., a domestic medical device enterprise in the field of orthopedic minimally invasive devices, announced the official introduction of Decheng Capital to complete a new round of investment of 100 million yuan, and China Renaissance Capital served as the exclusive financial adviser of Langmai Medical in the transaction.
Langmai Medical is a developer of orthopedic minimally invasive devices, integrating R&D, manufacturing, sales and service, focusing on the research and development and manufacture of products in the field of minimally invasive spine. By applying industry-leading technology to the company's product design and development, we are committed to providing orthopedic patients with a complete set of solutions for minimally invasive spine.
Jingyu Medical: Completed a D+ round of financing of 300 million yuan, and deeply cultivated the field of deep brain stimulation treatment
On February 16, Jingyu Medical announced the successful completion of a RMB 300 million D+ round of financing, jointly led by Sequoia China and Hillhouse Venture Capital.
This financing is another successful financing of Jingyu Medical after Yanchuang Capital led the completion of the D round of financing of more than 100 million yuan in April 2020. China Renaissance Capital acted as the sole financial advisor.
Jingyu Medical is an innovative high-tech medical device enterprise integrating R&D, production and sales, which has been deeply cultivating the field of deep brain stimulation therapy for many years, and leading the frontier exploration of invasive brain-computer interfaces for medical use.
Zhongjing Pukang: Obtained tens of millions of yuan of A round of financing to promote the approval and commercialization of three types of early screening products for bowel cancer
On February 14, Zhongjing Pukang, which focuses on the early detection of blood test CRC, completed tens of millions of yuan A round of financing.
This round is led by Hongrun Venture Capital, followed by Zhongguancun Qihang and Zhongguancun Synergy Fund, and the historical shareholders also include Taiyu Investment and Tengye Venture Capital. This round of financing will be mainly used to promote the clinical trial and commercialization of the three types of certificates.
Zhongjing Pukang is a tumor early screening service provider, mainly to provide users with a series of cancer risk assessment models, the use of B-GPS precision medicine core tools, through the wind assessment, can find a person in a certain period of time stage with a certain risk of a disease, and get personalized prevention advice, the current product has colorectal cancer risk assessment model.
Medical services
Tianrui Diagnostics: Completed a 100 million yuan B+ round of financing, committed to medical diagnostic services
On February 14, Tianrui Diagnostics, a provider of medical diagnostic service solutions, announced the completion of a 100 million yuan B+ round of financing.
This round of financing is jointly led by Wuxi Guolian Guokang Fund, Dingqi Jinma Fund, and Jiangsu Haoquan Lingang Industrial M&A Fund under YingXinxin Capital, followed by Wuxi Hesheng Investment, and the old shareholder Jin Yu Maowu continued to increase.
Tianrui Diagnostics is a leading comprehensive service provider of medical diagnosis overall solutions in China, and has become an innovator in the precision medicine diagnosis industry with its unique business model of "precision medical intelligent diagnosis + Internet service platform", and is committed to providing medical institutions with laboratory medicine + imaging medical services.
Qiyi Medical: Completed the Pre-A round of financing to strengthen the research and development of digital therapy products
On February 18, Qiyi Medical, which focuses on the whole process management system for respiratory diseases and digital therapy platform, announced the completion of tens of millions of yuan Pre-A round of financing, which was jointly invested by Yuanhe Origin and Seasonal Venture Capital, and the old shareholder Jingwei Venture Capital increased, and Weikuai Capital served as the exclusive financial advisor.
Founded in April 2020, Qiyi Medical is a medical artificial intelligence technology company based on real-world research data, and currently focuses on the development of disease management systems and digital diagnosis and treatment products in the field of respiratory chronic diseases, solving the core pain points of respiratory chronic disease diagnosis and management.
